Results 201 to 210 of about 35,333 (282)

Editorial for BBRC lipidomics special issue

, 2018
Sarah Spiegel, James M. Ntambi
openalex   +2 more sources

Untargeted Metabolomics Identifies N‐Lactoyl‐Amino Acids as Dose‐Responsive Plasma Biomarkers of Metformin Adherence in Type 2 Diabetes

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1057-1069, April 2026.
Metformin is the most widely prescribed antidiabetic drug, yet adherence remains difficult to objectively assess. Using untargeted metabolomics and lipidomics, we analyzed plasma from 637 patients with type 2 diabetes (T2D) with confirmed metformin use and 143 nondiabetic controls, annotating 614 metabolites.
Tomas Cajka, Jiri Hricko, Lucie Rudl Kulhava, Michaela Paucova, Michaela Novakova, Veronika Hola, Stanislava Rakusanova, Oliver Fiehn, Vojtech Skop, Ivana Lankova, Iva Miskova, Terezie Pelikanova, Martin Haluzik   +12 more
wiley   +1 more source

Integrated transcriptomic, metabolomic and lipidomic analysis revealed unique metabolic profile of regulatory T cells upon activation 3421 [PDF]

Yohei Sato, Misa Yura, Y Hanawa, Akihito Tsubota   +3 more
openalex   +1 more source

Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Sarcopenia is an age‐related condition characterized by progressive muscle mass, strength and physical performance declines, contributing to frailty and adverse health outcomes. Despite increasing interest in molecular biomarkers, longitudinal data with external validation are limited.
Sung Hye Kong, Ok Hee Jeon, Ji Yeon Kim, Miji Kim, Jinhee Kim, Seung Shin Park, Hak Chul Chang, Chang Won Won, Dohyun Han   +8 more
wiley   +1 more source

Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets. [PDF]

Int J Mol Sci
Maresca V, Bastonini E, Cardinali G, Flori E, Kovacs D, Ottaviani M, Briganti S.   +6 more
europepmc   +1 more source

Phospholipid Glutathione Peroxidase Overexpression Mitigates Cancer Cachexia by Protecting Muscle Mass and Lowering Inflammation

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Cancer cachexia is a muscle wasting syndrome that occurs in ~80% of cancer patients and is the primary cause of death for 22%–30% of cancer patients. The primary challenge associated with cancer cachexia is that effective therapies to treat the associated muscle loss and dysfunction are lacking.
Elizabeth Duggan, Jordan D. Fuqua, Bo Hagy, Constantin Georgescu, Benjamin F. Miller, Holly Van Remmen, Jacob L. Brown   +6 more
wiley   +1 more source

Integration of network pharmacology, metabolomics and lipidomics for clarifying the role of sphingolipid metabolism in the treatment of liver cancer by regorafenib

Hua Mu, Jinlong Hu, Zhikun Lin, Letian Wei, Qi Li, Xiaolin Wang, Pengyu Geng, Rui Zhong, Shimeng Cui, Wenru Liu, Chunxiu Hu, Guowang Xu, Guang Tan   +12 more
openalex   +1 more source

A complete workflow for high-resolution spectral-stitching nanoelectrospray direct-infusion mass-spectrometry-based metabolomics and lipidomics

, 2017
Andrew D. Southam, Ralf J. M. Weber, Jasper Engel, Martin R. Jones, Mark R. Viant   +4 more
openalex   +2 more sources

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently redefined from non‐alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L‐α‐lysophosphatidylinositol/G protein‐coupled receptor 55 (LPI/GPR55) axis, an element of the endocannabinoidome, has emerged as a key
Jerome Lian, Ricky R Lareu, Mohan Patil, Marco Falasca   +3 more
wiley   +1 more source

Understanding lipidomics associations and the lipoprotein-related caveats in population epidemiology. [PDF]

Am J Epidemiol
Zhao S, Ohukainen P, Kettunen J, Järvelin MR, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Mäkinen VP, Ala-Korpela M.   +9 more
europepmc   +1 more source